Daily non-political popular news in brief.
Jefferson pharmacologist says biomarker discovery bodes well for better cancer diagnostics
05-01-2007 · EurekAlert!A pharmacologist at the Kimmel Cancer Center at Jefferson says that new findings suggesting a genetic marker can help distinguish between chronic pancreatitis and pancreatic cancer and gauge who will do well with cancer treatment have important implications for improved cancer diagnostics and tumor profiling. In an editorial he co-authored May 2 in JAMA, Scott Waldman, M.D., Ph.D., says that researchers at Ohio State University have identified "a new level of biological regulation."
Read more »
Keywords: jefferson, pharmacologist, biomarker, discovery, bodes, cancer, diagnostics, bode, diagnostic
« Previous | Next »
Similar news on "Jefferson pharmacologist says biomarker discovery bodes well for better cancer diagnostics":
- Scientists identify a gene that may suppress colorectal cancer
03-21-2007 · EurekAlert!
In Genome Research, a husband-and-wife research team from Thomas Jefferson University report the discovery of a gene that, when mutated, may suppress colorectal cancer. To conduct the study, the researchers used a strain of mice that develop polyps, or small growths of tissue, in the digestive tract -- the harbingers of cancer. When these mice possessed one copy of the mutated gene, the incidence of small intestinal and colon polyps were reduced by about 90 percent.
Similar news · Read more »
- Scientists take next step in understanding potential target for Ovarian cancer treatment
07-16-2007 · EurekAlert!
A traffic cop protein in the cell may have an even more important role: transporting a messenger protein that tells components in the nucleus to stop cell growth. Scientists are studying the normal function of a protein called 'km23', the traffic cop protein, because the team previously found altered forms of the protein in 42 percent of tumor tissue samples taken from women with Ovarian cancer. The discovery of this additional role may lead to diagnostic tools and earlier treatments for Ovarian cancer.
Similar news · Read more »
- Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
09-23-2007 · EurekAlert!
Italian scientists will announce on Monday (Sept. 24) that they have found a new and promising target for anti-tumor therapy in cancer. Professor Saverio Alberti, from the CESI, University of Chieti Foundation, Chieti, will tell the European Cancer Conference that he and his team have found a widespread mechanism for the stimulation of tumor growth in man, and that this is leading to the development of novel diagnostic and therapeutic procedures.
Similar news · Read more »
- New molecules discovered that block cancer cells from modifying cell DNA
10-11-2007 · EurekAlert!
Researchers have discovered new small molecules that may prevent prostate cancer cells from turning off normal genes in a process that transforms normal cells into cancer cells. This significant discovery in the field of epigenetics has immediate implications in the development of new diagnostic tests and cancer medications.
Similar news · Read more »
- Ovarian cancer may mimic fallopian tube formation
03-06-2007 · EurekAlert!
A new study suggests that ovarian cancer cells form by hijacking a developmental genetic process normally used to form fallopian tubes. The discovery not only provides a new target for diagnostic and therapeutic interventions, but also opens new avenues for basic research in ovarian cancer pathology.
Similar news · Read more »
- Jefferson scientist's patent dramatically improves
07-18-2007 · EurekAlert!
A basic scientist at Jefferson Medical College and the Kimmel Cancer Center at Jefferson, has shared a patent on what may someday be a ubiquitous tool in DNA analysis. He and a colleague at Johns Hopkins University, have developed a technique that makes a DNA separation technique called electrophoresis, five times faster and less expensive than is is possible. The discovery could have a range of applications, from forensics, to cloning, and also to bioterrorism.
Similar news · Read more »
- Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
08-08-2007 · EurekAlert!
Today Almac Diagnostics announced a major study analyzing ductal carcinoma in situ tissue samples using its novel Breast Cancer DSA microarray. DSA research tools focus on the transcriptome of an individual disease, in this case breast cancer, and contain significant additional data relevant to the disease of interest that is not available on other generic microarrays.
Similar news · Read more »
- OHSU researchers: Surgery, radiation gives early survival advantage in bile duct cancer
10-28-2007 · EurekAlert!
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer. "Surgery and radiotherapy shows an early response benefit. It shows that the addition of radiation is potentially reasonable for the first-line treatment," said Clifton David Fuller, M.D., Ph.D., principal investigator of the study.
Similar news · Read more »
- Uninsured, others less likely to receive breast cancer test
12-03-2007 · EurekAlert!
An American Cancer Society study finds breast cancer patients who lack insurance, who come from areas with lower education levels, who are African-American, or who are older are less likely to get a key diagnostic test to make appropriate treatment decisions.
Similar news · Read more »
- Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
12-31-2007 · EurekAlert!
Scientists at Jefferson's Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely difficult-to-treat cancer.
Similar news · Read more »
